Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833311 | 1.00 | MEN1 (0.46) | MEN1CYP1A2KMT2AHTTCA1 | |
| SCHEMBL4833417 | 1.00 | MEN1 (0.46) | MEN1CYP1A2KMT2AHTTCA1 | |
| SCHEMBL2532757 | 1.00 | MEN1 (0.46) | MEN1CYP1A2KMT2AHTTCA1 | |
| SCHEMBL4841239 | 1.00 | MEN1 (0.46) | MEN1CYP1A2KMT2AHTTCA1 | |
| SCHEMBL12223219 | 0.82 | HTT (0.43) | HTTCA1CA2CA7CA9 | |
| SCHEMBL20530471 | 0.79 | CA1 (0.50) | MEN1KMT2AHTTCA1CA2 | |
| SCHEMBL20530469 | 0.79 | CA1 (0.50) | MEN1KMT2AHTTCA1CA2 | |
| SCHEMBL20530467 | 0.79 | CA1 (0.50) | MEN1KMT2AHTTCA1CA2 | |
| SCHEMBL20530465 | 0.79 | CA1 (0.50) | MEN1KMT2AHTTCA1CA2 | |
| SCHEMBL20530473 | 0.79 | CA1 (0.50) | MEN1KMT2AHTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867321-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | CYP4F11, CYP51A1, CYP4A11 | MEN1 2907/4885CYP1A2 101/4885KMT2A 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.